A retrospective analysis found levels of lipid-based biomarkers such as eicosanoids and sphingolipids were linked with risk of the condition.
Immune Biomarkers Could Predict First-Line Chemo Response in Pancreatic Cancer, Study Suggests
Premium
The researchers found patients who responded to first-line chemo had increased T-cell infiltration and enrichment of immune-related genes.
European Commission Approves Menarini's Orserdu for ESR1-Mutated Breast Cancer
In the Phase III EMERALD trial, patients with advanced ER-positive breast cancer with an ESR1 mutation fared better when treated with Orserdu than those on standard therapy.
Expert Panel Publishes Guidelines for Genetic Testing, Counseling in ALS
Recommendations call for testing all people with ALS and seek to harmonize laboratory testing and reporting practices.
CHMP Recommends Takeda's Adcetris, Chemo for CD30-Positive Stage III Hodgkin Lymphoma
CHMP recommended approval based on data from a Phase III trial evaluating Adcetris plus chemo for previously untreated patients.
Myriad Genetics, Memorial Sloan Kettering Partner to Study MRD Testing in Breast Cancer
The collaborators will evaluate the use of Myriad's MRD platform in predicting response to CDK4/6 inhibitors and in a chemotherapy neoadjuvant setting.